Recursion Pharmaceuticals Inc vs Silicon Motion Technology Corporation American Depositary Shares — how do they compare? Recursion Pharmaceuticals Inc trades at $3.68 (market cap $2.08B), while Silicon Motion Technology Corporation American Depositary Shares trades at $216.9 (market cap $8.36B). The key difference: Silicon Motion Technology Corporation American Depositary Shares is far larger — about 4× Recursion Pharmaceuticals Inc's market cap, and Silicon Motion Technology Corporation American Depositary Shares pays a 0.81% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Silicon Motion Technology Corporation American Depositary Shares for 0 Days on average.
| RXRX | SIMO | |
|---|---|---|
Market Cap | $2.08B | $8.36B |
Volume | 19,700,033 | 663,682 |
Sector | Health | Technology |
52-Week High | $6.79 | $336.90 |
52-Week Low | $2.84 | $80.16 |
Typical Hold Time | 22 Days | 0 Days |
Enterprise Value | $1.60B | $8.35B |
Dividend Yield | — | 0.81% |
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.835, down 4.36% today, with technical indicators showing a bullish trend despite recent weakness. The company reported revenue of $74.26M in 2025 but posted a significant net loss of -$644.76M, reflecting negative profit margins. Recent news highlights strategic AI partnerships and pipeline expansion, though the stock faces high short interest and ongoing operational losses.
Outlook remains speculative with 40% analyst buy ratings but substantial financial losses. Key opportunities include AI-driven drug discovery partnerships, while risks involve cash burn, competitive pressures, and delayed profitability. The stock's valuation at 36.1x sales appears stretched given current financial performance.
Silicon Motion (SIMO) trades at $246.63, down 0.13% on the day, with technical indicators showing neutral signals. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $2.43 versus $2.13, and revenue growth projected to reach $1.3B in 2026. Analyst sentiment remains overwhelmingly positive with 81% buy ratings and a consensus price target of $356.25, representing 44% upside potential from current levels.
The outlook for SIMO appears favorable given accelerating enterprise storage demand and AI infrastructure expansion. Key risks include semiconductor cycle volatility and competitive pressures in NAND controllers. With robust profitability metrics including 31.6% ROE and expanding margins, the stock offers growth exposure to the AI storage market, though investors should monitor execution on Q3 2026 earnings expectations of $3.3 EPS.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →Silicon Motion Technology Corporation designs and develops NAND flash controllers for solid-state storage, with flagship SSD, eMMC, and UFS controller products, including its Ferri-branded automotive and industrial storage solutions, used by OEMs and NAND flash makers worldwide.
Read more on SIMO →